Randomized Phase II Trial Compares Low-Dose Breast Cancer Prevention Drugs
Background
While Tamoxifen and Exemestane are established therapies for breast cancer, their use in prevention for high-risk post-menopausal women is often limited by significant side effects. This is particularly relevant for individuals with risk factors like atypical lobular hyperplasia, BRCA2 mutation, or CHEK2 gene mutation. This trial aims to determine if lower, less toxic doses of these drugs can still effectively reduce breast cancer risk in high-risk post-menopausal women, addressing a critical need for more tolerable preventative strategies.
Study Design
Results
This study is currently "NOT_YET_RECRUITING" (estimated start 2026-09-09), so no results are available yet. However, the trial is meticulously designed to investigate the efficacy and safety of low-dose preventative treatments for breast cancer. The primary objective is to compare the incidence of breast cancer (including ductal carcinoma and estrogen-receptor-positive breast cancer) between the Exemestane and Tamoxifen arms over the 12-month intervention period. Researchers will also assess secondary endpoints such as the occurrence of adverse events, impact on quality of life, and changes in relevant biomarkers. The central aim is to determine if a predetermined low dose of Exemestane or Tamoxifen can significantly reduce the risk of breast cancer in high-risk post-menopausal women, potentially offering a safer and more tolerable preventative option. The trial will compare the 12-month incidence rates between the two groups, aiming to identify if one treatment demonstrates a statistically significant reduction in risk compared to the other, with an estimated 140 participants providing initial insights.
Why It Matters
This Phase II trial is profoundly important because it seeks to identify a safer, more tolerable preventative strategy for breast cancer in high-risk post-menopausal women. Current preventative doses of Exemestane and Tamoxifen can have significant side effects, such as hot flashes, joint pain, or increased risk of blood clots, often limiting patient adherence and broader adoption. If these "baby" doses prove effective with fewer side effects, it could revolutionize breast cancer prevention by offering a more accessible and sustainable option for a broader population. Successful outcomes from this trial would pave the way for larger Phase III clinical trials to confirm efficacy and safety in a more diverse population, potentially leading to new clinical guidelines.